Homepage
Author:
AiCuris Anti-infective Cures AG
Posted Date:
April 16, 2026
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
AiCuris Anti-infective Cures AG
April 16, 2026
Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1
AiCuris Anti-infective Cures AG
February 25, 2026
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
AiCuris Anti-infective Cures AG
February 8, 2026
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
AiCuris Anti-infective Cures AG
January 29, 2026
